Stoke Therapeutics (STOK) Free Cash Flow Growth (5y) (2023 - 2026)
Stoke Therapeutics (STOK) Free Cash Flow Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.54% |
| Dec 31, 2025 | -23.36% |
| Sep 30, 2025 | -22.75% |
| Jun 30, 2025 | -21.40% |
| Mar 31, 2025 | 70.00% |
| Dec 31, 2024 | -16.78% |
| Sep 30, 2024 | -20.10% |
| Jun 30, 2024 | -21.33% |
| Mar 31, 2024 | -29.98% |
| Dec 31, 2023 | -42.06% |
| Sep 30, 2023 | -37.76% |